Original Investigation | Infectious Diseases Assessment of the Appropriateness of Antimicrobial Use in US Hospitals



Abstract (continued)

JAMA Network Open. 1 1 ._1 1 V._. 1

Introduction

| The second s |
|--|
| the second s |
| · · · · · · · · · · · · · · · · · |
| after the second s |
| ······································ |
| · · · · · · · · · · · · · · · · · · · |
| · · · · · · · · · · · · · · · · · · · |
| no se the second se |
| · · · · · · · · · · · · · · · · · · · |
| |
| fference in the second s |
| |
| |
| ······································ |
| |
| and the second |
| |
| |
| |
| the second s |
| |
| e and the second s |
| the second s |
| te an entre a construction and the second |
| |

Methods

Hospitals and Patients

| and the second |
|--|
| and the second of the second sec |
| · · · · · · · · · · · · · · · · · · · |
| ······································ |
| ····· · · · · · · · · · · · · · · · · |
| ···_· f ···· f. "···· |
| and the second for a second |
| the second s |
| |

Data Collection

| 11. | <u>f</u> | . <u></u> <i>f</i> . |
|-----|-------------------|----------------------|
| | I and a second as | |
| | | |
| | f | |

| supported |
|--|
| · · · · · · · · · · · · · · · · · · · |
| |
| |
| ······································ |
| · f f |
| a service a service a service a service of the serv |
| · · · · · · · · · · · · · · · · · · · |







Patients Included in Multiple AQUA Pathways



Discussion

| · · . | | - · · · | - | . 1 | | |
|-------|------|---------|---|---------|----|--|
| | | | | | | |
| | | | | | % | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | 1 | |
| | | | | | 11 | |

Table 2. Percentage of Antimicrobial Treatment Supported or Unsupported Based on Medical Record Documentation in the CAP Analysis Pathway

| Pathway criterion | Patients, No. (%) (n = 219) | Prescribing quality determination |
|---|--------------------------------|-----------------------------------|
| No pathogens identified from respiratory or sterile site cultures $i_{\mbox{\scriptsize M}}$ first 5 hospital d | | |
| ja first 5 hospital d | 171 (78.1) | NA |
| bld not received diddline-similar CAP treatment on day 3 of inpatient on | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| and the second |
|--|
| .f |
| a second a s |
| |
| the second s |
| for a second |

| a . a | | · | ſ |
|---------------------------|-----------------------|-------|-----|
| | | | |
| · · · · · · · · · · · · · | - · · · · | | · · |
| | · · · · f · · · · · · | _ 1_1 | |
| . f | · · · · · - | · ··· | |
| .f f | I in a second | | |




Table 5. Percentage of Antimicrobial Treatment Supported or Unsupported Based on Medical Record Documentation in the Vancomycin Analysis Pathway

| Pathway criterion | Patients, No. (%) (n = 403) | Prescribing quality determination |
|--|--------------------------------|-----------------------------------|
| Neutropenia | 7 (1.7) | Supported |
| Cystic fibrosis with a history of MRSA colonization or infection | 2 (0.5) | Supported |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Table 5. Percentage of Antimicrobial Treatment Supported or Unsupported Based on Medical Record Documentation in the Vancomycin Analysis Pathway (continued)

| | Patients, No. (%) | | |
|-------------------|--|----------------------------|--|
| Pathway criterion | (n. (%) | | |
| | (nT5l.ercentag0 14T 24T 0 1.0 14Tres14.bir | ndr . 15cmOuor c5 os9. (te | r) 1 1559cia(1100 1.0 142.1 1 4 592.(N |

| ···· f. · · · · · · · · · · · · · · · · |
|--|
| f |
| |
| ·f · . f · _ · · · · · · · · |
| <u>f</u> |
| · · · · · · · · · · · · · · · · · · · |
| afi in a construction of the second sec |
| |
| for a second |
| and the state of the second state of the secon |
| f Saureus, Pseudomonas aeruginosa f |
| the second s |
| f 1 % f |
| 1 1%. f |
| f |
| |
| |
| |
| t in the second s |
| · · · · f. · · · · · · · · · · · · · · · |
| |
| ······································ |
| |
| |

| % | f. f |
|---------------------------------------|------|
| · · · · · · · · · · · · · · · · · · · | 11 |
| %. f | |
| | |
| | |
| 1 | |
| | |
| f | |

Limitations

| and the second |
|--|
| <u> </u> |
| f_{-} |
| 1 |
| |
| The second s |
| · · · · · · · · · · · · · · · · · · · |
| the second and the second s |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| |
| f |
| |
| i i i i i i i i i i i i i i i i i i i |
| · · - · |

Conclusions

| f |
|---|
| · · · · · · · · · · · · · · · · · · · |
| |
| |
| · · · · · · · · · · · · · · · · · · · |
| en la francia en la construcción de |
| a f , f |
| ff f |
| |

ARTICLE INFORMATION

| Accepted for Pu | ublication: | | 1 | | | |
|---------------------------|-------------|--------|-----|-----|----------|---------|
| Published: | 1 1. | _1 1 V | | . t | | |
| Open Access: JAMA Netv | | ··· - | | · | .1 | 1 |
| Corresponding | Author: | | | f | - | . £ |
| | 1 | 1 | 1 . | | _ | |

_ . . 1 _ . . f

.

REFERENCES

| 7 Clin Infect Dis 1 | | |
|------------------------|--|--|
| | | |

| .1 . | N Engl J Med | 1 | 1 11 | 1 | . 1.1 | 1 | 1.1 | 1 | |
|------|--------------|---|------|---|-------|---|-----|---|--|
| 9 | | | | | | | | | |

25 Staphylococcus aureus 1 1 1 1 4 M J Health Syst Pharm 1 . ___ . . Clin Infect Dis 1 1 1 1 29 *f Clin Infect Dis f 1 1* 11 / ./ . 1 32 Infect Control Hosp Epidemiol 1 1 1 1 1 1 1/ 1 11 34